XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 7 - Subsequent Events
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Subsequent Events [Text Block]

Note 7:    Subsequent Events

 

Management continues to monitor the COVID-19 pandemic and its development, and the possible effects on the Company’s financial condition, liquidity, operations, vendors, industry, and workforce. 

 

For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through  November 10, 2022, the date the consolidated financial statements were available to be issued. Except as discussed below, management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.

 

On October 27, 2022, the Company announced that it has received regulatory approval for the Company’s Clinical Trial Application (CTA) from the South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial using our DYAI-100 COVID-19 Receptor Binding Domain (RBD) booster vaccine.